News

Under the terms of the agreement, Gilead will provide an upfront payment of $10 million. Additionally, Hookipa will be eligible to receive milestone payments based upon the achievement

The Swiss drugmaker had submitted a supplemental biologics license application to the US regulator, covering the data recorded from the phase 3 Haven 3 study. Hemlibra’s priority review

Fulphila, which secured approval to reduce the duration of febrile neutropenia in patients treated with chemotherapy in certain types of cancer, has been co-developed by Mylan and Biocon. It is

This new funding will enable the company to finance the two first Phase II clinical trial of its EYP001 asset in both chronic hepatitis B (HBV) and NASH.

The first investigational product, LBL100 (3% bupivacaine in Lipogel), is being developed as a long-acting local anesthetic for post-operative pain. Virpax expects to file a Pre-Investigational New Drug

Lynparza is a poly ADP-ribose polymerase (PARP) inhibitor co-developed by AstraZeneca with Merck. Abiraterone is the standard-of-care treatment in mCRPC. The combination of Lynparza and abiraterone was evaluated

High risk of recurrence is defined as lymph node-positive or hormone receptor-negative disease. The Perjeta-based regimen should be administered for a total of one year (up to 18

MONALEESA-3 showed Kisqali plus fulvestrant significantly prolonged progression-free survival (PFS) compared to fulvestrant alone in postmenopausal women with hormone-receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced

The approval is for a 2mg dose of the drug in adult patients who did not show adequate response to one or more tumor necrosis factor (TNF) inhibitor